A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

NCT05109702 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: 0.25% Tanfanercept Ophthalmic Solution
DRUG: Placebo

Sponsor

HanAll BioPharma Co., Ltd.

Collaborators

[object Object]